^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    FATE-NK100

    i
    Associations
    News

    Trials

    Company:
    Fate Therap, University of Minnesota
    Drug class:
    NK cell stimulant, Cell therapy
    Related drugs:
    Associations
    News

    Trials

    Apply
    FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors (NCT03319459)
    Phase 1
    Fate Therapeutics
    Completed
    Last update posted :
    11/22/2021
    Initiation :
    01/18/2018
    Primary completion :
    05/29/2020
    Completion :
    12/15/2020
    EGFR • HER-2
    |
    Herceptin (trastuzumab) • Erbitux (cetuximab) • FATE-NK100